Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,635 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation.
Katsuyama N, Kawase T, Barakat C, Mizuno S, Tomita A, Ozeki K, Nishio N, Sato Y, Kajiya R, Shiraishi K, Takahashi Y, Ichinohe T, Nishikawa H, Akatsuka Y. Katsuyama N, et al. Among authors: mizuno s. Nagoya J Med Sci. 2023 Nov;85(4):779-796. doi: 10.18999/nagjms.85.4.779. Nagoya J Med Sci. 2023. PMID: 38155626 Free PMC article.
Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation.
Sakurai M, Mori T, Kato K, Kanaya M, Mizuno S, Shiratori S, Wakayama T, Uchida N, Kobayashi H, Kubo K, Amano I, Ohta T, Miyazaki Y, Kanda J, Fukuda T, Atsuta Y, Kondo E; Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Sakurai M, et al. Among authors: mizuno s. Bone Marrow Transplant. 2021 Jun;56(6):1462-1466. doi: 10.1038/s41409-020-01192-8. Epub 2021 Jan 29. Bone Marrow Transplant. 2021. PMID: 33514920 No abstract available.
Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
Kamijo K, Shimomura Y, Shinohara A, Mizuno S, Kanaya M, Usui Y, Kim SW, Ara T, Mizuno I, Kuriyama T, Nakazawa H, Matsuoka KI, Kusumoto S, Maseki N, Yamaguchi M, Ashida T, Onizuka M, Fukuda T, Atsuta Y, Kondo E. Kamijo K, et al. Among authors: mizuno i, mizuno s. Ann Hematol. 2023 Mar;102(3):651-661. doi: 10.1007/s00277-023-05084-x. Epub 2023 Jan 12. Ann Hematol. 2023. PMID: 36631705 Free PMC article.
Advantages of Higher Busulfan Dose Intensity in Fludarabine-Combined Conditioning for Patients with Acute Myeloid Leukemia Undergoing Cord Blood Transplantation.
Shibata S, Arai Y, Kondo T, Mizuno S, Harada K, Miyakoshi S, Uchida N, Maruyama Y, Eto T, Katsuoka Y, Matsue K, Nishiwaki K, Takada S, Doki N, Itoh M, Nagafuji K, Kawakita T, Tanaka J, Fukuda T, Atsuta Y, Yanada M. Shibata S, et al. Among authors: mizuno s. Transplant Cell Ther. 2023 May;29(5):332.e1-332.e11. doi: 10.1016/j.jtct.2023.02.004. Epub 2023 Feb 14. Transplant Cell Ther. 2023. PMID: 36796517 Free article.
Efficacy and safety of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients aged > 65 years with unfavorable cytogenetics.
Yamasaki S, Mizuno S, Iwasaki M, Seo S, Uchida N, Shigesaburo M, Nakano N, Ishiwata K, Uehara Y, Eto T, Takase K, Kawakita T, Tanaka M, Sawa M, Katayama Y, Nawa Y, Makoto O, Ichinohe T, Atsuta Y, Kanda J, Yanada M. Yamasaki S, et al. Among authors: mizuno s. Ann Hematol. 2023 Jun;102(6):1549-1559. doi: 10.1007/s00277-023-05243-0. Epub 2023 May 1. Ann Hematol. 2023. PMID: 37126115
Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation.
Barakat C, Inagaki Y, Mizuno S, Nishio N, Katsuyama N, Sato Y, Kobayashi M, Ozeki K, Iida H, Tomita A, Sawa M, Demachi-Okamura A, Takahashi Y, Nishikawa H, Akatsuka Y. Barakat C, et al. Among authors: mizuno s. Int J Hematol. 2023 Aug;118(2):252-266. doi: 10.1007/s12185-023-03621-y. Epub 2023 Jun 13. Int J Hematol. 2023. PMID: 37310580
Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs.
Takamatsu H, Matsuda T, Mizuno S, Takahashi T, Fuchida SI, Hanamura I, Kataoka K, Tsukada N, Matsumoto M, Hangaishi A, Doki N, Uchida N, Sawa M, Maruyama Y, Kurahashi S, Nagafuji K, Harazaki Y, Kako S, Iida S, Ichinohe T, Kanda Y, Atsuta Y, Sunami K; Multiple Myeloma Working Group in the Japanese Society for Transplantation and Cellular Therapy. Takamatsu H, et al. Among authors: mizuno s. Haematologica. 2023 Dec 1;108(12):3399-3408. doi: 10.3324/haematol.2023.283202. Haematologica. 2023. PMID: 37470160 Free PMC article.
Reappraising the prognostic relevance of cytogenetic risk in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
Mizuno S, Hosoi H, Takami A, Kawata T, Doki N, Takeda W, Tanaka M, Nishida T, Uchida N, Hasegawa Y, Sawa M, Ota S, Onizuka M, Nakamae H, Asada N, Fukuda T, Yoshimitsu M, Kanda Y, Ohbiki M, Atsuta Y, Konuma T, Yanada M. Mizuno S, et al. Ann Hematol. 2024 Dec;103(12):5903-5913. doi: 10.1007/s00277-024-06094-z. Epub 2024 Nov 19. Ann Hematol. 2024. PMID: 39560740
Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma.
Okada Y, Kimura F, Kurita N, Takahashi H, Shimazu Y, Mizuno S, Uchida N, Kataoka K, Hiramoto N, Ota S, Kako S, Tsukada N, Kanda Y, Kurahashi S, Doki N, Nishikawa A, Kim SW, Hangaishi A, Kanda J, Fukuda T, Atsuta Y, Kondo E, Kawamura K, Nakasone H. Okada Y, et al. Among authors: mizuno s. Cytotherapy. 2023 Nov;25(11):1212-1219. doi: 10.1016/j.jcyt.2023.05.015. Epub 2023 Jun 24. Cytotherapy. 2023. PMID: 37354150
Allogeneic hematopoietic stem cell transplantation using reduced intensity conditioning regimen for patients with acute myeloid leukemia not in complete remission.
Shimomura Y, Kitamura T, Yanada M, Mizuno S, Kondo T, Yoshihara S, Tanaka M, Inai K, Katayama Y, Onizuka M, Fukuda T, Nakamae H, Kurokawa M, Yano S, Nara M, Masuko M, Miyakoshi S, Eto T, Yoshimitsu M, Ishimaru F, Kanda J, Atsuta Y, Konuma T. Shimomura Y, et al. Among authors: mizuno s. Cytotherapy. 2024 Nov 17:S1465-3249(24)00937-X. doi: 10.1016/j.jcyt.2024.11.012. Online ahead of print. Cytotherapy. 2024. PMID: 39625431
2,635 results